MedTrace Logo

Nivestim™ in Treatment of Malignant Diseases

NCT01627990 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 386

Last updated 2015-07-24

No results posted yet for this study

Summary

The purpose of this study is to observe the tolerability, safety and efficacy of preventative treatment using Nivestim™ in patients receiving cytotoxic chemotherapy for cancer.

Conditions

  • Solid Tumour
  • Malignant Haematological Tumour
  • Primary or Secondary Prophylactic Treatment

Sponsors & Collaborators

  • Hospira, now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01627990 on ClinicalTrials.gov